StockNews.AI
LFCR
StockNews.AI
145 days

Lifecore Biomedical to Report Financial Results for Third Quarter of Fiscal 2025 on April 3, 2025

1. Lifecore will announce Q3 fiscal results on April 3, 2025. 2. Webcast at 4:30 p.m. ET will discuss financial results. 3. Lifecore specializes in injectable pharmaceutical manufacturing. 4. Company has over 40 years of industry experience. 5. Focus on differentiated development for biopharmaceutical products.

3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results could positively influence investor sentiment, similar to past earnings that reflected growth.

How important is it?

The announcement of earnings results is critical for assessing Lifecore's current financial health and prospects.

Why Short Term?

The impending earnings report will likely impact stock value shortly after its release.

Related Companies

AMGNREGNPTCT
CHASKA, Minn., March 27, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it will report financial results for the third quarter of fiscal year 2025 on Thursday, April 3, 2025, after market close. At 4:30 p.m. Eastern Time that day, members of Lifecore’s senior management team will host a webcast to discuss financial results for the quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please visit the Investor Events & Presentations page of Lifecore’s website at: https://ir.lifecore.com/events-presentations. Following the live webcast, an archived version of the webcast will be available on the company’s website for 30 days.    About Lifecore Biomedical Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Related News